Emicizumab Replaces Factor VIII Function in Hemophilia A Emicizumab Replaces Factor VIII Function in Hemophilia A

The bispecific monoclonal antibody emicizumab replaced the function of factor VIII in people with hemophilia A and overcame neutralizing antibodies against factor VIII, results of the HAVEN 1 trial show.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news